Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations.

Here we describe the successful use of intravenous immunoglobulin (IVIG) in the management of mycoplasma-induced, atypical Stevens-Johnson syndrome (SJS) with minimal skin manifestations. The patient was successfully managed with high-dose IVIG 0.5 g/kg for 4 consecutive days. No complications were noted. IVIG may be useful in the management of mycoplasma-induced SJS.